Twist Bioscience Corp

For the period ended Sep 30, 2024. Filed Nov 18, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Nov 18, 2024

TWST$120.79+0.1%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

November 18, 2024	Twist Bioscience Corporation
	By:	/s/ Emily M. Leproust
		Emily M. Leproust
		Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated:

Nelson C. Chan
Signature	Title	Date
/s/ Emily M. Leproust	Chief Executive Officer and	November 18, 2024
Emily M. Leproust	Chair of the Board of Directors (principal executive officer)
/s/ Adam Laponis	Chief Financial Officer (principal financial	November 18, 2024
Adam Laponis	officer)
/s/ Robert F. Werner	Chief Accounting Officer (principal	November 18, 2024
Robert F. Werner	accounting officer)
/s/ Nelson C. Chan	Director	November 18, 2024
/s/ Robert Chess	Director	November 18, 2024
Robert Chess
/s/ Keith Crandell	Director	November 18, 2024
Keith Crandell
/s/ Jan Johannessen	Director	November 18, 2024
Jan Johannessen
/s/ Xiaoying Mai	Director	November 18, 2024
Xiaoying Mai
/s/ Robert Ragusa	Director	November 18, 2024
Robert Ragusa
/s/ Melissa Starovasnik	Director	November 18, 2024
Melissa Starovasnik

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.